(APDNW) Launches DNA Mark Identification Technology Platform — DNA Beacon(TM)

Encrypted Fluorescence Is Covert, Mobile and Adaptable Across Many Industries

investor contact:
Debbie Bailey
631-240-8817
Email contact

media contact:
Enrique Briz
Dian Griesel Int’l.
212-825-3210
Email contact

program contact:
Judy Murrah
CIO
631-240-8819
Email contact

(EGRX) & (TEVA) License to Commercialize Bendamustine Rapid Infusion Product

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) today announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle’s bendamustine hydrochloride (HCl) rapid infusion product for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva.

Eagle has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the rapid infusion bendamustine product for the treatment of patients with CLL and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Eagle has requested Priority Review of the NDA; this product candidate has received Orphan Drug Designations for both CLL and indolent B-cell NHL, and therefore may be eligible for seven years of exclusivity upon approval. The NDA is supported by data from Eagle’s recently-completed clinical trials demonstrating that the rapid infusion bendamustine HCl product can be administered in ten minutes in a low-volume, 50 mL admixture.

“Since 2008, Teva’s bendamustine HCl product, TREANDA^®, has played a valuable role in the treatment of patients with CLL or indolent B-cell NHL that has progressed,” stated Paul Rittman, Vice President and General Manager, Teva Oncology. “With a substantially shorter infusion time, Eagle’s rapid infusion bendamustine HCl represents an important and improved benefit to both patients and healthcare providers. By adding this product to Teva’s Oncology portfolio, we are furthering our commitment to enhancing treatment options for patients affected by cancer and executing on a business development strategy to pursue opportunities in therapeutic areas where we can apply our expertise, commercial infrastructure and experience.”

“We are very pleased to partner with Teva for the commercialization of our rapid infusion bendamustine product,” said Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals. “Given their strong presence and unsurpassed knowledge of this market, we believe there is no better company than Teva to optimize the market potential of this product.”

As part of the agreement, Teva will waive its orphan drug exclusivities for NHL and CLL with respect to EP-3102, which should allow the product to come to market more quickly. Under the terms of the exclusive license agreement, Eagle will receive an upfront cash payment of $30 million and is eligible to receive up to $90 million in additional milestone payments. In addition, Eagle will receive double-digit royalties on net sales of the product, assuming FDA approval.

The companies will also settle the pending patent infringement action between them in the United States District Court for the District of Delaware involving Teva’s U.S. Patent No. 8,791,270.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.

About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA’s 505(b)(2) regulatory pathway. Eagle currently markets RYANODEX^® (dantrolene sodium) in the U.S. for the treatment of malignant hyperthermia. Additional information is available on the company’s website at www.eagleus.com.

RYANODEX^® is a registered trademark of Eagle Pharmaceuticals, Inc.

TREANDA^® (bendamustine HCI) Injection Indications
TREANDA^® is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

TREANDA^® is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

• Allergic Reactions: Patients with a known allergic response to bendamustine should not take TREANDA^®.
• Serious Side Effects: TREANDA^® may cause serious side effects, including low blood cell counts, infections, unexpected responses to TREANDA^® when placed in your blood, sudden and severe allergic responses, kidney failure due to fast breakdown of cancer cells, other cancers, and leaking of TREANDA^® out of your vein and into your surrounding skin. Some of these side effects, such as low blood counts, infections, and severe allergic skin responses (when TREANDA^® was given with allopurinol and other medications known to cause severe allergic skin responses), have caused death. Tell your doctor right away if you have any of these side effects.
• Changes in Therapy: Some serious side effects may require changes in therapy, such as lowering the amount of TREANDA^® given, stopping the use of TREANDA^® or waiting longer than expected between doses of TREANDA^®.
• Pregnancy: Women should avoid becoming pregnant while using TREANDA^® because it may cause fetal harm if you take TREANDA^® while pregnant.
• Most Common Side Effects: The most common non-blood-related side effects associated with TREANDA^® (occurring in ≥15% of patients) are nausea, fatigue, vomiting, diarrhea, fever, constipation, loss of appetite, cough, headache, weight loss, difficulty breathing, rash, and mouth irritation. The most common blood-related side effects associated with TREANDA^® (frequency ≥15%) are decreased number of three different types of white blood cells (infection-fighting cells), low red blood cells (oxygen-carrying cells), and low platelets (blood-clotting cells).

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for TREANDA^® Full Prescribing Information.

TREANDA^® is a registered trademark of Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd.

Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements, which are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our innovative products, especially Copaxone^® (including competition from orally-administered alternatives, as well as from potential purported generic equivalents) and our ability to migrate users to our new 40 mg/mL version; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from the research and development efforts invested in our pipeline of specialty and other products; our ability to reduce operating expenses to the extent and during the timeframe intended by our cost reduction program; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2014 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Eagle’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words such as “will,” “may,” “intends,” “anticipate(s),” “plan,” “enables,” “potentially,” “entitles,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events including, but not limited to: acceptance for filing by the FDA of the NDA for the rapid infusion bendamustine product for the treatment of patients with CLL and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen; the decision of the FDA on Eagle’s request for Priority Review for this NDA; success in gaining timely FDA approval of the rapid infusion bendamustine product for the treatment of patients with CLL and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen; the timing and level of success of a future launch of the rapid infusion bendamustine product by Teva; the success of Eagle’s commercial arrangement with Teva and the parties’ ability to work effectively together; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; and other factors that are discussed in Eagle’s Annual Report on Form 10-K for the year ended September 30, 2014, and its other filings with the U.S. Securities and Exchange Commission. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to: whether the FDA will accept Eagle’s NDA for the rapid infusion bendamustine product for the treatment of patients with CLL and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen; whether the FDA will grant Priority Review of the NDA or whether the FDA will ultimately approve the NDA, at all; whether Teva will be successful at commercializing the rapid infusion bendamustine product; whether Eagle and Teva will successfully perform each of their respective obligations under the exclusive license agreement; and other risks described in Eagle’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin C. Mannix, 215-591-8912
or
United States
Ran Meir, 215-591-3033
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
Israel
Iris Beck Codner, 972 (3) 926-7687
or
United States
Denise Bradley, 215-591-8974
or
United States
Nancy Leone, 215-284-0213
or
Eagle
In-Site Communications
Lisa Wilson, 212-452-2793
or
Amy Raskopf, 917-673-5775

(ROSG) Announces Key Patent Allowances in U.S. and Europe

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming the use of miR-34a for the treatment of p53-associated cancers. In addition, the Company announced its first allowance from the European Patent Office for a patent claiming the specific composition for miR-451, a miR relating to the Company’s Cancer of Unknown Primary (CUP) testing franchise.

The allowed claims for the U.S. Patent Application No. 14/280,822 entitled “Composition and Methods For Modulating Cell Proliferation and Cell Death” cover a core element of Rosetta Genomics’ microRNA technology in the development of cancer therapeutics relating to cancers associated with the p53 gene. This patent is broader than the previous patent issued last year in that it covers the treatment of any p-53 associated cancer using miR-34a or its variants, delivered by any kind of formulation.

The patent is jointly owned with Yeda Research and Development, the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel.

The p53 protein is a sequence-specific transcription factor that functions as a major tumor suppressor in mammals. Inactivation of the p53 tumor-suppressor function is one of the most frequent genetic alterations in human cancer, and more than half of all human tumors carry p53 gene mutations within their cells. In addition, mutations in p53 have been correlated with clinical aggressiveness.

“p53 plays an important role in many cancers. Consequently, a therapeutic based on mimicking miR-34a that can potentially overcome some of the negative effects of mutations in this important tumor suppressor holds significant promise,” commented E. Robert Wassman, M.D., Rosetta Genomics’ Chief Medical Officer.

The allowed claims for European Patent Application Number 05766834.5 entitled, “MicroRNAs and uses thereof” cover miR-451 and its complement, as well as a probe comprising the claimed miR. Therapeutic and diagnostic uses of the miR and/or the probe are also covered in the allowed claims.

“We continue to fortify our leading intellectual property position in microRNA technology as well as microRNAs themselves and these new patents expand, strengthen and complement our growing portfolio of over 40 patents worldwide,” noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “Patents such as this recent one in the U.S. are important as they not only protect key elements of our microRNA technology to develop a variety of oncology treatments that are associated with the p53 tumor suppressor, but they also offer multiple opportunities for monetization through potential drug development partnerships or other licensing arrangements. Separately, this recent European composition of matter patent strengthens and expands the patent protection for our CUP testing franchise and further establishes our global leadership position in microRNA technology.”

“Importantly, both of these patents support our broader oncology strategy to develop and commercialize microRNA-based diagnostics, therapeutics and biomarkers on a global basis in order to enhance clinicians’ ability to identify and treat cancers,” concluded Mr. Berlin.

About Rosetta Cancer Testing Services

Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to asbestos exposure. The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. Rosetta’s assays are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test™, 60,000 from the Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The Company’s assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta’s cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, Rosetta’s Cancer of Origin Test™, Rosetta’s development or commercialization of molecular diagnostics or therapeutics, the market acceptance of Rosetta’s cancer testing services, particularly the Rosetta Cancer Origin Test™, Rosetta’s development of personalized medicine products and services, the reproducibility, robustness and accuracy of Rosetta’s microRNA technology and its ability to help enable personalized medicine and optimize treatment, the expansion of payor coverage of Rosetta’s testing services, and the amount of people covered for the Rosetta testing services, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the “Risk Factors” section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2013 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

(CAPN) Announces First U.S. Commercial Sales of CoSense(R)

REDWOOD CITY, Calif., Feb. 17, 2015  — Capnia, Inc. (Nasdaq:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced the first U.S. commercial sales of the Company’s CoSense End-Tidal Carbon Monoxide (ETCO) Monitors and single-use sampling sets to leading academic, research and healthcare institutions. CoSense is a portable, non-invasive device that rapidly and accurately measures carbon monoxide in exhaled breath. The measurement of carbon monoxide is the gold standard for measuring hemolysis, a condition that, if left untreated, may lead to elevated levels of bilirubin in the blood and a range of neurodevelopmental disorders in newborns.

“We have made significant progress to date with the U.S. commercialization of CoSense, the only available device for accurately and non-invasively measuring ETCO in newborns,” said Anish Bhatnagar, M.D., Chief Executive Officer of Capnia. “These first customers, which include a prestigious academic institution and an internationally recognized nonprofit hospital system, underscore the potentially significant and diversified markets for this unique device. As we continue to execute our staged commercial rollout of CoSense, we remain focused on our goal of making this important product widely available.”

Of the 140 million babies born worldwide and 9.2 million babies born annually in the in the U.S. and European Union, more than 60% will present with jaundice at some point in the first five days of life. Jaundice is caused by the pigment bilirubin and may be a sign of excessive breakdown of red blood cells, or hemolysis. In infants, bilirubin is toxic to the brain and central nervous system. Exposure to high levels of bilirubin in newborns may lead to permanent neurological damage. These neurological abnormalities range from subtle ones such as learning disabilities and impaired hearing to severe life threatening outcomes such as acute bilirubin encephalopathy, or a chronic disabling disease called kernicterus.

The American Academy of Pediatrics guidelines state that ETCO monitoring is the only clinical test that provides a direct measurement of the rate of bilirubin production, and therefore hemolysis. The guidelines recommend ETCO measurement be performed to assess the presence of hemolysis in neonates in several clinical circumstances. CoSense is the only available device to accurately measure the ETCO levels in neonates and therefore the only device that enables physicians to practice in accordance with the AAP guidelines when evaluating jaundiced neonates for potential treatment.

About Hemolysis

Hemolysis refers to the rapid or excessive breakdown of red blood cells, a process which produces bilirubin at an accelerated rate, resulting in jaundice. Approximately 60% of healthy infants and 80% of premature infants have jaundice during the neonatal period. Many causes of jaundice do not represent a significant health threat, yet it is the most common cause of hospital readmission for newborns. Severe jaundice in the presence of hemolysis is a predictor of adverse neurodevelopmental outcomes such as low IQ, auditory abnormalities and kernicterus. Rapid diagnosis and treatment of this condition may be necessary for infants to avoid life-long neurological impairment or other disability.

About Capnia

Capnia, Inc. develops and commercializes novel products based on its proprietary technologies for precision metering of gas flow. Capnia’s lead product is CoSense, which aids in the detection of hemolysis, a dangerous condition in which red blood cells degrade rapidly. CoSense, based on the Sensalyze™ Technology platform, is a portable non-invasive device that rapidly and accurately measures carbon monoxide in exhaled breath. CoSense has 5010(k) clearance from the FDA and also received CE mark approval for sale in the E.U. Capnia’s proprietary therapeutic technology uses nasal, non-inhaled CO₂ to treat symptoms of allergies, as well as the trigeminally-mediated pain conditions such as cluster headache, trigeminal neuralgia and migraine.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned product development and clinical trials and that measuring ETCO may be an effective way to identify pathological hemolytic conditions.

We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Additional factors that could materially affect actual results can be found in Capnia’s Form S-1 filed with the Securities and Exchange Commission on November 14, 2014, including under the caption titled “Risk Factors.” Capnia expressly disclaims any intent or obligation to update these forward looking statements, except as required by law.

CONTACT: Capnia Contact:
         David O'Toole
         Chief Financial Officer
         Capnia, Inc.
         (650) 353-5146
         dotoole@capnia.com

         Investor Relations Contact:
         Michelle Carroll/Susie Kim
         Argot Partners
         (212) 600-1902
         michelle@argotpartners.com
         susie@argotpartners.com

(VSTA) NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

Similar to Ketamine, AV-101 Has a Fundamentally Novel Mechanism of Action Compared to All Approved Antidepressants

(BBEP) Conference Call & Webcast to Discuss Q4 and Year-End 2014 Results

Breitburn Energy Partners LP (NASDAQ:BBEP) will hold a conference call on Tuesday, March 3, 2015, at 10 am (PST) following the release of its fourth quarter and year-end 2014 financial results.

The conference call may be accessed by calling 888-539-3612 (international callers dial 719-325-2244) or via webcast at http://ir.breitburn.com/. An archived edition of the conference call will also be available through March 10, 2015, by calling 877-870-5176 (international callers dial 858-384-5517) and entering replay PIN 8598867 or by visiting http://ir.breitburn.com/.

About Breitburn Energy Partners LP

Breitburn Energy Partners LP is a publicly-traded, independent oil and gas master limited partnership focused on the acquisition, development, and production of oil and gas properties throughout the United States. Breitburn’s producing and non-producing crude oil and natural gas reserves are located in the following seven producing areas: the Permian Basin, Michigan/Indiana/Kentucky, Ark-La-Tex, the Mid-continent, the Rockies, Florida, and California. See www.breitburn.com for more information.

Cautionary Statement Regarding Forward-Looking Information

This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that Breitburn expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by Breitburn based on management’s experience and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond Breitburn’s control and are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. The reader should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Unless legally required, Breitburn undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Unpredictable or unknown factors not discussed herein also could have material adverse effects on forward-looking statements. See “Risk Factors” in Breitburn’s Annual Report filed on Form 10-K and other public filings and press releases.

BBEP-IR

(LBTYB) & Virgin Media Announce Huge Investment in UK’s Internet Infrastructure

Virgin Media, the UK’s ultrafast internet provider, is embarking on “Project Lightning” the single largest investment in broadband digital infrastructure in the country for more than a decade; creating thousands of new jobs in what will be a multi-billion pound boost to the national economy.

With the support of parent company Liberty Global plc (“Liberty Global”) (Nasdaq: LBTYA, LBTYB, LBTYK), Virgin Media will extend its unrivalled fibre-rich network to approximately four million additional premises over the next five years. This will increase the number of homes and businesses to which Virgin Media can offer services by almost a third; from around half of the country today to nearly 17 million premises by 2020.

£3 billion for homes and businesses; £8 billion of value to the UK economy and consumers

The UK is the world’s most internet-based major economy (Source: Ofcom). Broadband infrastructure, and the services offered over it, will be increasingly central to the country’s growth over the coming decades.

The £3 billion of additional private investment announced today is essential for individuals and businesses to thrive in the global digital economy. This substantial investment will be financed mainly through incremental borrowings. Analysis undertaken by leading economic consultancy Oxera has found that this investment can be expected to stimulate a combined £8 billion of economic activity and consumer benefit.

Prime Minister David Cameron said: “I welcome this substantial investment from Virgin Media which is a vote of confidence in our long-term economic plan to support business and create jobs by building a superfast nation backed by world-class infrastructure. These 6,000 new jobs and apprenticeships will mean financial security and economic peace of mind for thousands more hardworking families across the country. Together with this Government’s rollout of superfast broadband which has now reached more than two million UK homes and businesses, this additional private investment will create more opportunities for people and businesses, further boosting our digital economy and helping secure a brighter future for Britain.”

Tom Mockridge, Virgin Media Chief Executive Officer, said: “Millions of homes and businesses will soon be able to benefit for the first time from broadband speeds at least twice as fast as those available from the other major providers. Consumers and business owners who want to make the switch to better broadband speeds now have an alternative; you can call on Virgin Media to ‘Cable My Street’.”

Mike Fries, Liberty Global Chief Executive Officer, said: “Our next-generation fibre-rich networks reach 50 million households across Europe, enabling our customers to discover and experience the endless possibilities of the digital world. After a record operating performance, Project Lightning is a significant investment that demonstrates the confidence we have in Virgin Media and the UK as a place to do business.”

Households connecting to Virgin Media for the first time will benefit from broadband speeds of 152Mb, at least twice as fast as the fastest speeds available from BT, TalkTalk and Sky. Virgin Media also offers the UK’s most advanced interactive television service, bringing together broadcast TV, thousands of hours of on demand programming and the best of the web in a single set-top box.

Home workers and small and medium-sized companies will also receive a boost from better connectivity in areas where Virgin Media Business will become available for the first time.

When it comes to making the most of increasingly connected lives, speed and capacity matters. The number of internet-enabled devices has grown significantly in the past decade, as homes and businesses are increasingly connected to multiple devices simultaneously. Sixty per cent of Virgin Media customers now have at least three devices connected to their home broadband, up from 37 per cent a year ago. Data usage on the Virgin Media network is currently growing at a rate of around 60 per cent every year which, if this trend continues, will be 10,000 per cent higher in ten years.

6,000 UK jobs created; award-winning apprenticeship scheme expanded

This network expansion programme is expected to create 6,000 new jobs in the UK at Virgin Media and across its construction partners. Roles will be created across the country, including jobs to support engineering and sales efforts.

It will increase the number of apprenticeships created by Virgin Media to 1,000 over the next five years. Almost 1,000 young people have already gained recognised skills and experience in this award-winning scheme while earning, since it began in 2008. Further information about working for Virgin Media is available at virginmedia.com/careers.

Virgin Media calls on consumers and businesses to register their interest

Network expansion will be prioritised according to demand from households and companies, with a focus on areas closest to Virgin Media’s existing network.

Virgin Media is urging communities who want better connectivity to register their interest at virginmedia.com/cablemystreet.

Businesses can register at virginmediabusiness.co.uk/cablemybusiness.

Tom Mockridge, Virgin Media Chief Executive Officer, added: “In virtually all of the areas we have identified for expansion, BT is the only option available right now. Its ageing copper telephony wires are not capable of the ultrafast connectivity that Virgin Media delivers. Soon we will offer unbeatable services to even more homes and businesses across the country.”

Long term investment in speed leadership; Virgin Media – always faster

Today’s announcement of “Project Lightning” marks a five-year transformation of Virgin Media to extend its existing position as ‘always faster’ to more areas as the better alternative to the incumbent BT’s network.

Liberty Global is a global leader in innovation and new technologies and is preparing trials of DOCSIS 3.1 technology across Europe later this year. This technology could extend Liberty Global’s speed leadership to up to 10Gb when it is fully deployed in the future.

Virgin Media Business – transforming the prospects of enterprise

Virgin Media Business offers telecoms services specifically designed to help small and medium companies grow. These are tailored to cover those starting out, as well as growing, emerging and maturing businesses, helping to reduce complexity and make it easier for firms to seize business opportunities every day.

A new proposition specifically designed for the start-up hotspot of east London means Virgin Media Business is installing managed internet access to buildings with shared occupancy. Once the fibre is installed, each of the small businesses in a building will get their own dedicated connection. There are plans to extend this multi-tenant capability across other parts of the UK.

Notes to Editors

Ofcom: Importance of the UK’s internet economy revealed, December 2014 http://media.ofcom.org.uk/news/2014/icmr-2014/

Virgin Media is already in the process of expanding its network to 110,000 homes across east London, Glasgow, Sunderland and Teesside.

About Virgin Media

Virgin Media is the first provider of all four broadband, TV, mobile phone and home phone services in the UK. The company’s cable network – the result of multi-billion pound private investment – delivers ultrafast broadband to over half of all UK homes, with speeds of up to 152Mb, as well as market leading connectivity to thousands of public and private sector organisations across the country.

Virgin Media has developed the most advanced interactive television service, bringing together broadcast TV, thousands of hours of on demand programming and the best of the web in a single set-top box powered by TiVo. The company was the first to offer HD TV and 3D on demand to millions of British households.

The world’s first virtual mobile network was launched by Virgin Media and it is also one of the largest fixed-line home phone providers in the country.

Virgin Media is a part of Liberty Global plc, the world’s largest international cable company. Together Virgin Media and Liberty Global serve 27 million customers across 14 countries, helping connect people to the digital world and enabling them to discover and experience its endless possibilities.

Disclaimer

This press release contains forward-looking statements, including statements regarding Virgin Media’s investment plans and programme to extend its internet infrastructure, the amount of the investment, the timing and phasing of the investment and roll-out of broadband services, the number of homes and businesses to be reached as a result of the investment programme and the economic benefits and impacts of such investment, and other information and statements that are not historical fact. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. These risks and uncertainties include the continued use by subscribers and potential subscribers of our services and their willingness to upgrade to our more advanced offerings, our ability to meet challenges from competition, to manage rapid technological change or to maintain or increase rates, general economic factors, the continued growth in services for digital television at a reasonable cost, the effects of changes in laws or regulation, our ability to successfully acquire attractive programming for our digital video services and the costs associated with such programming, our ability to maintain certain accreditations, our ability to achieve expected operational efficiencies and economies of scale, our ability to generate expected revenue and operating cash flow, control property and equipment additions as measured by a percentage of revenue, the impact of our future financial performance, or market conditions generally, on the availability, terms and deployment of capital, fluctuations in currency exchange and interest rates, the ability of vendors and suppliers to timely deliver quality products, as well as other factors detailed from time to time in our most recent quarterly and annual report and Liberty Global’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date of this release. We expressly disclaim any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

(OCLR) Prices Offering of $55 Million of 6.00% Convertible Senior Notes Due 2020

SAN JOSE, Calif., Feb. 13, 2015  — Oclaro, Inc. (Nasdaq: OCLR), announced today the pricing of its offering of $55,000,000 aggregate principal amount of 6.00% Convertible Senior Notes due 2020 (the “Convertible Notes”). The Convertible Notes will be offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), by the initial purchaser of the Convertible Notes. Oclaro has also granted the initial purchaser of the Convertible Notes a 30-day option to purchase up to an additional $10,000,000 aggregate principal amount of the Convertible Notes.

Oclaro intends to use the net proceeds of the offering for general corporate purposes, including working capital.

The Convertible Notes will mature on February 15, 2020 and will bear interest at a fixed rate of 6.00% per year, payable on February 15 and August 15 of each year, beginning August 15, 2015. The Convertible Notes will be general senior, unsecured obligations of Oclaro. The Convertible Notes will not be redeemable at Oclaro’s option prior to February 15, 2018. On or after February 15, 2018, the Convertible Notes will be redeemable at Oclaro’s option if the last reported sale price of Oclaro’s common stock for at least 20 trading days (which need not be consecutive trading days) in any 30 trading day period exceeds 130% of the conversion price for the Convertible Notes. The redemption price will equal 100% of the principal amount of the Convertible Notes being redeemed, plus accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date plus the sum of the present values of each of the remaining scheduled payments of interest that would have been made on the Convertible Notes being redeemed had such Convertible Notes remained outstanding from the redemption date to the maturity date. In addition, upon the occurrence of a fundamental change, holders of the Convertible Notes will have the right, at their option, to require Oclaro to repurchase their Convertible Notes in cash at a price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The Convertible Notes will be convertible, at the option of the holders, into consideration consisting of, shares of Oclaro’s common stock (and cash in lieu of fractional shares) at any time prior to the close of business on the business day immediately preceding the maturity date. Prior to February 15, 2018, in the event that the last reported sale price of our common stock for 20 or more trading days (whether or not consecutive) in a period of 30 consecutive trading days ending within five trading days immediately prior to the date we receive a notice of conversion exceeds the conversion price in effect on each such trading day, we will, in addition to delivering shares upon conversion by the holder of the Convertible Notes, together with cash in lieu of fractional shares, make an interest make-whole payment. The initial conversion rate will be 512.8205 shares of Oclaro’s common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $1.95 per share of Oclaro’s common stock), representing an approximately 33.6% conversion premium to the $1.46 last reported sale price of Oclaro’s common stock on The NASDAQ Global Select Market on February 12, 2015. The conversion rate will be subject to adjustment upon the occurrence of certain events. In addition, Oclaro may be obligated to increase the conversion rate for any conversion that occurs in connection with a make-whole fundamental change and with Oclaro’s delivery of a notice of redemption for the Convertible Notes.

The offering is being made to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Neither the Convertible Notes nor any shares of Oclaro’s common stock issuable upon conversion of the Convertible Notes have been or will be registered under the Securities Act or under any state securities laws and, unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

Safe Harbor Statement
This press release contains forward-looking statements for the purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995.  Such statements can be identified by the fact that they do not relate strictly to historical or current facts and may contain words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “will,” “should,” “outlook,” “could,” “target,” “preliminary” and other words and terms of similar meaning in connection with any discussion of plans, objectives, goals, strategies and future operating or financial performance.  Undue reliance should not be placed on such forward-looking statements, which speak only as of the date they are made. Oclaro undertakes no obligation to update such forward-looking statements. Actual events and results may differ materially from those in the forward-looking statements and are subject to risks and uncertainties. Such risks and uncertainties include, but are not limited to, whether or not Oclaro will offer the Convertible Notes or consummate the offering, the anticipated terms of the Convertible Notes and the offering and the anticipated use of the proceeds of the offering.

(APTO) Appoints Dr. Bradley Thompson to the Audit Committee

SAN DIEGO and TORONTO, Jan. 20, 2015  – Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, announced today that Dr. Bradley Thompson has been appointed to the Audit Committee, and that the NASDAQ Stock Market (“NASDAQ”) has notified the Company it has regained compliance with Listing Rule 5605 to maintain three independent members on the Audit Committee.

On December 15, 2014, Dr. Brian Underdown, a member of the Board of Directors and Audit Committee, resigned from the Aptose Board of Directors in conjunction with the appointment of Dr. Erich Platzer to the Board. This left the Audit Committee with only two independent members until Dr. Bradley Thompson was formally appointed to the committee. As previously reported on January 15, 2015 in the Company’s 6K filing with the Securities and Exchange Commission, on January 13, 2015 the Company received, as expected, a notification letter from NASDAQ stating that the Company no longer complied with NASDAQ’s audit committee requirements of maintaining committee membership by at least three independent directors as set forth in Listing Rule 5605 due to the resignation of Dr. Brian Underdown,  which was previously reported on December 15, 2014, in its Form 6-K filing with the Securities and Exchange Commission. The NASDAQ letter was issued in accordance with standard NASDAQ procedures.

Consistent with Listing Rule 5605(c)(4), NASDAQ provided the Company a cure period in order to regain compliance as follows:

• until the earlier of the Company’s next annual shareholders’ meeting or December 15, 2015; or
• if the next annual shareholders’ meeting is held before June 15, 2015, then the Company must evidence compliance no later than June 15, 2015.

On January 16, 2015 the Company appointed Dr. Bradley Thompson to the Audit Committee and was notified by NASDAQ today that the Company has regained compliance with Listing Rule 5605.

About Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies that address unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for its products. Aptose’s lead anticancer agent APTO-253 is under development for AML, MDS and other hematologic malignancies. For further information, please visit www.aptosebiosciences.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward looking statements could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

(FEYE) Global Threat Intel Sharing Initiative at White House Summit on Cybersecurity

FireEye Provides Platform for Broader Sharing of Its Industry Leading Threat Intelligence Obtained Through Advanced Threat Detection Capabilities

(ENTL) Announces Release of XprESS(TM) Ultra Multi-Sinus Dilation System

PLYMOUTH, Minn., Feb. 13, 2015  — Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced the release of the XprESS™ Ultra Multi-Sinus Dilation System, the third device in the XprESS family of balloon sinus dilation systems.

XprESS Ultra provides the precision, versatility and control of the XprESS family of balloon sinus dilation systems while adding an even sleeker profile device to the XprESS family. The sleek profile and design of XprESS Ultra allows for smooth movement through tight nasal passages and easy endoscopic viewing of the treatment area while the malleable tip can be reshaped to meet the unique challenges of patients with extremely narrow sinus drainage pathways. “Entellus makes very intuitive products. The XprESS Ultra is a thinner tool that makes tight access easier,” said Dr. Rajiv Pandit, MD, Dallas ENT, Dallas Sinus Institute. With the addition of XprESS Ultra, the XprESS family now offers a choice of features to address patient needs and meet physician preferences.

The XprESS family of products are used by Ear, Nose and Throat, or ENT, physicians to treat patients with symptomatic inflammation of the nasal sinuses and open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. “The addition of XprESS Ultra to the XprESS family of devices highlights our ongoing commitment to making it even easier for ENT specialists to offer the benefits of balloon sinus dilation to patients suffering from sinusitis,” said Robert White, President and Chief Operating Officer, Entellus Medical, Inc.

About Chronic Sinusitis and Balloon Sinus Dilation:

Chronic sinusitis affects approximately 29 million American adults, making it one of the most common health problems in the U.S. It is more prevalent than heart disease and asthma, and has a negative impact on quality of life with chronic symptoms and effects including facial pain and pressure, headaches, fatigue, loss of smell, and sinus infections.

Surgical treatment of chronic sinusitis routinely involves cutting and removal of sinus mucosal tissue near the opening of a sinus. Use of sinus balloon technology preserves the natural sinus anatomy and enables effective treatment of sinusitis patients in the comfort and convenience of a physician’s office. In-office balloon sinus dilation is a proven, effective alternative treatment to endoscopic sinus surgery and provides patients lasting relief at a lower cost than traditional sinus surgery.

About Entellus Medical:

Entellus Medical is a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical’s balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery, or FESS. Patients treated with Entellus Medical’s products in this trial in the ENT physician office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. Entellus Medical currently markets its products in the United States and Canada and sells its products through a direct sales force in the United States.

Forward-Looking Statements:

All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause the performance of the Entellus XprESS Ultra device or Entellus Medical’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the company’s significant operating expenses incurred since inception and expected to incur in the future; its dependence on a limited number of products, including the XprESS family of multi-sinus products; physicians’ willingness to change current practices and continue to adopt office-based balloon sinus dilation procedures; inability to maintain adequate levels of reimbursement for the procedures using the company’s products; the impact of competition within the industry; the company’s substantial dependence on a key license agreement; and the company’s ability to establish and maintain intellectual property protection for its products or avoid claims of infringement. Other factors that could cause actual results to differ materially from those contemplated in this press release can be found under the caption “Risk Factors” in the company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission, or SEC, and its other reports filed with the SEC. Entellus Medical undertakes no obligation to update or revise any forward-looking statements, even if subsequent events cause our views to change.

CONTACT: MEDIA CONTACT:
         Leigh Salvo 415-513-1281
         ir@entellusmedical.com

(TUBE) to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Feb. 12, 2015  — TubeMogul, Inc. (Nasdaq:TUBE), a leading enterprise software company for digital branding, today announced that members of the management team will present to the investment community at the following investor conferences:

Webcasts will be accessible on the investor relations section of the TubeMogul website (http://investor.tubemogul.com). Archived replays of the webcasts will be available following the live presentations.

About TubeMogul

TubeMogul (Nasdaq:TUBE) is a leading enterprise software company for digital branding. By reducing complexity, improving transparency and leveraging real-time data, our platform enables advertisers to gain greater control of their digital video advertising spend and achieve their brand advertising objectives. TubeMogul was incorporated in 2007 and is based in Emeryville, California with operations in New York, London, Singapore, Tokyo, Sydney, Toronto and offices across the United States.

TubeMogul and the TubeMogul logo are trademarks or registered trademarks of TubeMogul, Inc. in the United States and other countries.

CONTACT: Media Contact:
         David Burch
         press@tubemogul.com

         Investor Relations Contact:
         Alex Wellins
         The Blueshirt Group
         investor@tubemogul.com

(ZIOP) Announces Exercise of Option to Purchase Additional Shares

BOSTON, Feb. 12, 2015  — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that the underwriters for its recently announced underwritten public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock at a public offering price of $8.75 per share. Gross proceeds to ZIOPHARM from the sale of the additional shares are expected to be approximately $13.1 million before deducting underwriting discounts and commissions and estimated offering expenses payable by ZIOPHARM, bringing the total gross proceeds from the offering to $100.6 million. ZIOPHARM intends to use the net proceeds from the underwritten offering for general corporate and working capital purposes, including clinical development of its pipeline and development of technologies that it has licensed from The University of Texas M.D. Anderson Cancer Center.

J.P. Morgan Securities LLC acted as sole book-running manager for the offering and BMO Capital Markets Corp. acted as senior lead manager. Griffin Securities, Inc., Maxim Group LLC and Mizuho Securities USA Inc. acted as co-managers for the offering. The closing of the sale of the additional shares is expected to occur on or about February 17, 2015, subject to customary closing conditions.

The public offering is being made pursuant to an automatic shelf registration statement on Form S-3ASR previously filed with the Securities and Exchange Commission (the “SEC”), which became automatically effective upon filing.  The offering is being made only by means of a prospectus supplement.  The final prospectus supplement relating to the offering has been filed with the SEC.  Copies of the final prospectus supplement and accompanying prospectus may be obtained at the SEC’s website at www.sec.gov or from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 866-803-9204).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company that seeks to acquire, develop and commercialize, on its own or with commercial partners, a diverse portfolio of cancer therapies that can address unmet medical needs through synthetic biology.  Pursuant to an exclusive channel agreement with Intrexon Corporation, ZIOPHARM’s technology platform employs Intrexon’s RheoSwitch Therapeutic System^® technology to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The Company’s synthetic immuno-oncology programs in collaboration with Intrexon also include chimeric antigen receptor T cell (CAR-T) approaches that they have licensed from The University of Texas M.D. Anderson Cancer Center.

Forward-looking Statements

This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” the negative of these words and similar expressions intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the anticipated closing of the sale of the additional shares; the Company’s intended use of proceeds; the progress, timing and results of preclinical and clinical trials involving the Company’s drug candidates; the progress of the Company’s research and development programs; and the Company’s estimates of future revenues and profitability. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: risks related to market conditions and the satisfaction of customary closing conditions related to the underwriters’ exercise of their option, whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-IL-12, DC-RTS-IL-12, palifosfamide, darinaparsin, indibulin, or any of our other therapeutic products will advance further in the pre-clinical or clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-IL-12, DC-RTS-IL-12, palifosfamide, darinaparsin, indibulin, and our other therapeutic products will be successfully marketed if approved; whether any of our other therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our collaboration agreements; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; the development of, and our ability to take advantage of, the market for our therapeutic products; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

CONTACT: For more information about ZIOPHARM Oncology, contact:

         Lori Ann Occhiogrosso
         Director of Corporate Communication
         ZIOPHARM Oncology, Inc.
         617-259-1987
         locchiogrosso@ziopharm.com

         David Pitts or Eliza Schleifstein
         Argot Partners
         212-600-1902
         david@argotpartners.com
         eliza@argotpartners.com

(ATNM) Pivotal Trial of Iomab-B Briefing By Principal Investigator Dr. John Pagel Announced

Enthusiastic Interest in Event From Leading Physicians Representing High Volume Transplant Sites Bodes Well for Trial Enrollment

(SGMO) Presents Data At 11th Annual WorldSymposium On In Vivo Protein Replacement Platform

Novel ZFN Genome Editing Approach Results in Sustained Levels of Enzymes Associated with Hunter, Hurler and Gaucher Syndromes

RICHMOND, Calif., Feb. 12, 2015  — Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the presentation of preclinical data from its In Vivo Protein Replacement Platform (IVPRP) program for the development of proprietary ZFP Therapeutics^® for the potential cure of lysosomal storage disorders (LSDs). The study was presented at the WORLDSymposium^™ 2015 Meeting, a multidisciplinary forum presenting the latest information from basic science, translational research, and clinical trials for lysosomal diseases, which is being held in Orlando, Florida, from February 9-13, 2015. The data were generated by Sangamo scientists and their collaborators at the University of Minnesota and University of Massachusetts Medical School.

Data presented at WORLDSymposium^™ 2015 demonstrate that Sangamo’s zinc finger nuclease (ZFN) genome editing technology can specifically integrate into the albumin locus of normal mice, human genes encoding functional enzymes that are defective in the LSDs Hunter, Hurler and Gaucher syndromes. Following ZFN-mediated genome editing, robust levels of protein expression were observed in the liver, blood plasma and spleen, leading to increases in enzymatic activity of up to 100-fold. Furthermore, elevated enzyme activity in the blood plasma was sustained over the course of the two month study.

“For lysosomal storage diseases, the population in greatest need is small children. To intervene in the very young and achieve a long-lasting therapeutic effect from a single administration demands stability of enzyme expression over the lifetime of the patient. It is precisely this ability to drive a permanent change at the DNA level that is enabled by our ZFN-driven in vivo protein replacement strategy,” stated Philip Gregory, D. Phil., Sangamo’s senior vice president of research and chief scientific officer. “These data show substantial increases in the activity of the target enzymes in the liver, blood plasma, and spleen, consistent with the effective production, secretion, and importantly, uptake, of the functional therapeutic proteins by other cells and tissues of the body. Thus, by harnessing a tiny fraction of the liver’s powerful albumin promoter and synthesis pathway, we are able to produce sustainable levels of LSD enzymes for the potentially long-term treatment of various lysosomal storage disorders.”

“These data highlight that our proprietary ZFN-enabled genome editing technology can generate broadly applicable and disruptive approaches for the potential cure of numerous monogenic diseases including LSDs,” stated Edward Lanphier, Sangamo’s president and CEO. “Our goal is to move our Hunter and Hurler ZFN Therapeutic programs through IND-enabling studies in 2015.”

About Lysosomal Storage Disorders
Lysosomal storage disorders are a heterogeneous group of inherited genetic disorders, including Hunter, Hurler, and Gaucher syndromes, that are caused by defects in genes that encode enzymes that break down and eliminate unwanted substances in the cells of the body. These enzymes are found in structures called lysosomes which act as recycling sites in cells, breaking down unwanted material into simple products for the cell to reuse. A defect in a lysosomal enzyme leads to the accumulation of toxic levels of the substance that the enzyme would normally break-down and results in cell damage which can lead to serious health consequences.

There are nearly 50 LSDs altogether and they may affect different parts of the body, including the skeleton, brain, skin, heart and CNS. Currently, there are no cures for LSDs, and treatments have not yet been developed for many of these diseases. For certain disorders, including Hunter and Hurler syndromes, costly enzyme replacement therapies (ERTs) are available, but require frequent administration in order to be effective. Over time, patients may also develop an immunogenic response to the administered protein, rendering the ERT less efficacious.

Background on Sangamo’s IVPRP Approach
The IVPRP approach makes use of the albumin gene locus, a highly expressing and liver-specific genomic “safe-harbor site”, that can be edited with zinc finger nucleases (ZFNs) to accept and express any therapeutic gene. The platform enables the patient’s liver to permanently produce therapeutic levels of a corrective protein product such as factor VIII or IX to treat hemophilia, or replacement enzymes to treat lysosomal storage disorders. With such a large capacity for protein production (approximately 15g/day of albumin), which is in excess of the body’s requirements, targeting and co-opting only a very small percentage of the albumin gene’s capacity is sufficient to produce the needed replacement protein at therapeutically relevant levels with no significant effect on albumin production.

About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures^TM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has clinical stage programs to evaluate the safety and efficacy of novel ZFP Therapeutics^® for the treatment of HIV/AIDS (SB-728-T), beta-thalassemia (SB-BCLmR-HSPC), and NGF-AAV for Alzheimer’s disease (CERE-110). Sangamo’s other therapeutic programs are focused on monogenic and rare diseases. The Company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington’s disease and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company’s website at www.sangamo.com.

ZFP Therapeutic^® is a registered trademark of Sangamo BioSciences, Inc.

This press release may contain forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation, references relating to research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo’s ZFP technology platform; the potential of Sangamo’s ZFP technology to treat LSDs, Hunter, Hurler and Gaucher syndromes and the safety of the approach of using ZFP-mediated genome editing in vivo; the expected IND studies for Hunter and Hurler programs; and the applicability of Sangamo’s ZFP technology in monogenic diseases. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of our clinical trials, whether the clinical trials will validate and support the safety, tolerability and efficacy of ZFNs and ZFP TFs, technological challenges, Sangamo’s ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of these and other risks, please see Sangamo’s public filings with the Securities and Exchange Commission, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

(CVV) Reports $45 Million in 2014 Orders

CVD Equipment Corporation (Nasdaq: CVV) , a leading provider of standard and custom chemical vapor deposition systems, today announced that it received in excess of $45 Million in orders during 2014.

Leonard Rosenbaum, President and Chief Executive Officer stated, “CVD is continuing to experience high levels of orders and quote activity. We anticipate that this trend will continue into 2016 and beyond as orders for production and research equipment, including equipment for aerospace, medical devices, and nano materials, are continuing to drive our business forward. Our new facility is humming with activity, we have increased our production personnel by 13% over the past four months and our crew is working diligently to convert these orders into revenue.”

About CVD Equipment Corporation

CVD Equipment Corporation (NASDAQ: CVV) is a designer and manufacturer of custom and standard state-of-the-art equipment used in the development, design and manufacture of advanced electronic components, materials and coatings for research and industrial applications. CVD offers a broad range of chemical vapor deposition, gas control, and other equipment that is used by customers to research, design and manufacture semiconductors, solar cells, graphene, carbon nanotubes, nanowires, LEDs, MEMS, smart glass coatings, batteries, ultra capacitors, medical coatings, industrial coatings and equipment for surface mounting of printed circuit components. CVD’s application laboratory focuses on higher efficiency nano and nano to macro material manufacturing for a wide variety of growth markets, which are marketed through our wholly owned subsidiary CVD Materials Corporation.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by CVD Equipment Corporation) contains statements that are forward-looking. All statements other than statements of historical fact are hereby identified as “forward-looking statements, “as such term is defined in Section 27A of the Securities Exchange Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward looking information involves a number of known and unknown risks and uncertainties that could cause actual results to differ materially from those discussed or anticipated by management. Potential risks and uncertainties include, among other factors, conditions, success of CVD Equipment Corporation’s growth and sales strategies, the possibility of customer changes in delivery schedules, cancellation of orders, potential delays in product shipments, delays in obtaining inventory parts from suppliers and failure to satisfy customer acceptance requirements.

(HART) Pricing of Public Offering of Common & Series B Convertible Preferred Stock

Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today announced the pricing of its previously announced underwritten public offering. HART is offering 1,800,000 registered shares of its common stock at a price to the public of $1.75 per share, and 695,857 registered shares of its Series B Convertible Preferred Stock (“Series B”) at a price to the public of $8.75 per share, for expected gross proceeds of approximately $9.2 million. At the option of the investor, the Series B is convertible into five shares of common stock of the Company, and will vote with the common stock on all matters on an as converted basis. The Series B has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. In connection with the offering, HART has also granted the underwriter a 30-day option to purchase up to an additional 270,000 shares of common stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, including funding pre-clinical and clinical trials relating to the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes.

The offering is expected to settle and close on February 18, 2015, subject to the satisfaction or waiver of customary closing conditions. National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (OTCBB: NHLD) is acting as sole book runner in the offering and Summer Street Research Partners is acting as co- manager for the offering.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-200926), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on December 29, 2014. A final prospectus supplement describing the terms of the offering will be filed with the SEC. Any offer will be made only by means of a prospectus supplement and accompanying base prospectus forming a part of the effective registration statement. Before investing, you should read the prospectus supplement and the accompanying base prospectus, and other documents that HART has filed or will file with the SEC, for information about HART and this offering.

Once filed, copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting National Securities Corporation at the following address:

National Securities Corporation
410 Park Ave, 14th Floor
New York, NY 10022
Attn: Kim Addarich
Telephone: (212) 417-8164
Email: prospectusrequest@nationalsecurities.com

Investors may also obtain these documents for no charge by visiting the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of HART and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our HART-Trachea technology has been used in six human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Forward-Looking Statements

Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements in this press release include, but are not limited to, HART’s expectations regarding the completion, timing and size of its proposed public offering, whether expressed or implied, statements relating to the success with respect to any regulatory filings and approval pertaining to the HART-Trachea or any other HART products, by the FDA, MHRA, European Medicines Agency, or otherwise, which such filings or approvals may not be made or obtained on a timely basis or at all, and success with respect to clinical trials, commercialization efforts and marketing approvals of HART’s products, including our HART-Trachea product, which such success or approvals may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, HART’s ability to complete the offering, as well as the actual size and terms of the offering and its ability to raise additional capital, as well those factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. HART expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

(AREX) Announces Record Annual Production and Proved Reserves

Approach Resources Inc. (NASDAQ:AREX) today reported estimated fourth quarter and full-year 2014 production and reserves.

Production Highlights

• Fourth quarter production was 15.1 MBoe/d, a 34% increase over the prior-year quarter
• Full-year 2014 production was 5,049 MBoe, a 47% increase over the prior year
• Oil production was 2,024 MBbls, a 40% increase over the prior year
• Oil production represented 40% of total production for full-year 2014
• Drilled 68 horizontal wells and placed 64 horizontal wells on production
• 2014 capital expenditures of $393.5 million

Proved Reserves Highlights

• Year-end 2014 proved reserves grew to 146.2 MMBoe, a 27% increase over the prior year
• PV-10 (non-GAAP) was $1.4 billion, a 25% increase over the prior year

Management Comment

Ross Craft, Approach’s Chairman and CEO commented, “At the beginning of 2014 we set an ambitious goal of achieving a 40% annual production growth rate, while maintaining one of the lowest drilling and completion cost structures in the Permian Basin. Now with 12 months behind us, I am very pleased with the operational performance of our team. Not only were we able to beat our original production goal and deliver a 47% growth in production, but even more importantly, we were able to do that while controlling our capital costs, which came in below our original $400 million budget.

Looking ahead to 2015, our industry is presented with a different set of challenges, given the significant change in commodity prices. We continue to conservatively manage our balance sheet, and we remain flexible on our capital spending budget, particularly as we take proactive steps to further reduce our cost structure and enhance drilling economics. Most importantly, we have no near-term debt maturities, and our liquidity position is strong, providing the ability to weather a prolonged downturn in commodity prices and to take advantage of opportunities that may become available.”

Estimated Fourth Quarter and Full-Year 2014 Production

Estimated fourth quarter 2014 production totaled 1,390 MBoe (15.1 MBoe/d), a 34% increase over fourth quarter 2013 and a 6.4% increase over third quarter 2014. Estimated oil production for fourth quarter 2014 increased 14% compared to fourth quarter 2013 and 7.1% from third quarter 2014.

Estimated full-year 2014 production totaled 5,049 MBoe (13.8 MBoe/d), a 47% increase over 2013. Oil production for 2014 increased 40% compared to 2013.

2014 Estimated Proved Reserves and Costs Incurred

Year-end 2014 proved reserves totaled 146.2 MMBoe, up 27% from year-end 2013 proved reserves of 114.7 MMBoe. Our proved oil reserves increased 20% to 55.3 MMBbls, compared to year-end 2013 proved oil reserves of 46.1 MMBbls. Year-end 2014 proved reserves were 38% oil, 28% NGLs and 34% natural gas. Proved developed reserves represent approximately 41% of total year-end 2014 proved reserves, up from 39% at year-end 2013.

Preliminary, unaudited costs incurred during 2014 totaled $ 393.5 million and included $364 million for drilling and completion activities, $24.9 million for infrastructure projects and other equipment and $4.6 million for acreage acquisitions and lease extensions.

Conference Call Scheduled for Thursday, February 26, 2015

The Company plans to announce fourth quarter and full-year 2014 financial and operational results on Wednesday, February 25, 2015, after close of trading. In addition, the Company plans to host a conference call on Thursday, February 26, 2014, at 9:00 a.m. Central Time (10:00 a.m. Eastern Time) to discuss fourth quarter and full-year 2014 financial and operational results. Those wishing to listen to the conference call, may do so by visiting the Events page under the Investor Relations section of the Company’s website, www.approachresources.com, or by phone:

A replay of the call will be available on the Company’s website or by dialing:

Supplemental Non-GAAP Financial and Other Measures

PV-10

The present value of our proved reserves, discounted at 10% (“PV-10”), was estimated at $1.4 billion at December 31, 2014, and was calculated based on the first-of-the-month, 12-month average prices for oil, NGLs and gas, of $94.56 per Bbl of oil, $31.50 per Bbl of NGLs and $4.55 per MMBtu of natural gas.

PV-10 is our estimate of the present value of future net revenues from proved oil and gas reserves after deducting estimated production and ad valorem taxes, future capital costs and operating expenses, but before deducting any estimates of future income taxes. The estimated future net revenues are discounted at an annual rate of 10% to determine their “present value.” We believe PV-10 to be an important measure for evaluating the relative significance of our oil and gas properties and that the presentation of the non-GAAP financial measure of PV-10 provides useful information to investors because it is widely used by professional analysts and investors in evaluating oil and gas companies. Because there are many unique factors that can impact an individual company when estimating the amount of future income taxes to be paid, we believe the use of a pre-tax measure is valuable for evaluating the Company. We believe that PV-10 is a financial measure routinely used and calculated similarly by other companies in the oil and gas industry.

The Company has not provided a reconciliation of its PV-10 to our standardized measure of discounted future net cash flows, the most directly comparable measure calculated and presented in accordance with GAAP, in this release because final income tax information for 2014 is not yet available. The Company will provide its customary reconciliation of PV-10 to standardized measure in its forthcoming Form 10-K for the year ended December 31, 2014, to be filed with the SEC.

About Approach Resources

Approach Resources Inc. is an independent energy company focused on the exploration, development, production and acquisition of unconventional oil and gas reserves in the Midland Basin of the greater Permian Basin in West Texas. For more information about the Company, please visit www.approachresources.com. Please note that the Company routinely posts important information about the Company under the Investor Relations section of its website.

Forward-Looking and Cautionary Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by the Company based on management’s experience, perception of historical trends and technical analyses, current conditions, anticipated future developments and other factors believed to be appropriate and reasonable by management. When used in this press release, the words “will,” “potential,” “believe,” “estimate,” “intend,” “expect,” “may,” “should,” “anticipate,” “could,” “plan,” “predict,” “project,” “profile,” “model” or their negatives, other similar expressions or the statements that include those words, are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. Further information on such assumptions, risks and uncertainties is available in the Company’s Securities and Exchange Commission (“SEC”) filings. The Company’s SEC filings are available on the Company’s website at www.approachresources.com. Any forward-looking statement speaks only as of the date on which such statement is made and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

(NVGN) Lodges Key Super-benzopyran Patent

SYDNEY, Feb. 11, 2015  — Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the lodgement of final specifications of a patent that covers the Company’s first family of super-benzopyran compounds that to date has yielded leading drug candidates TRXE-002, TRXE-009 and TRXE-0025.

Super-benzopyrans represent a new chemical structure of increasing complexity and diversity. Based on the degree of that complexity, Novogen chemists have identified at least 6 patent families of related compounds. The final patent specifications just lodged represent the first of those families, with some hundreds of molecules designed and manufactured over the past 12 months. The focus with this particular family of compounds has been their ability to kill cancer stem cells. The underlying pharmacophore responsible for this activity has been identified and forms a key aspect of the patent.

Work is progressing on the remaining 5 potential patent families to determine the underlying pharmacophores relevant to various activities including the promotion of neurogenesis, to the promotion of functionality of stem cells with genetic abnormalities, and to the treatment of lysosomal storage diseases. Once those potential patent families have been reduced to practice, then the appropriate patents will be lodged.

Andrew Heaton PhD, Novogen Group Vice-President of Drug Discovery and Manufacture, said, “The last 12 months has been a highly productive time of reducing our super-benzopyran drug discovery program to practice, so allowing this PCT final specification to be lodged. Happily, we also are seeing these drugs successfully come through their large-scale manufacturing process ahead of a number of clinical trials over the next 12 months. We have not hit any manufacturing hurdles, confirming the simpler manufacturing process that is a key part of the patent.”

Graham Kelly PhD, Novogen Group CEO, said, “Andrew’s drug discovery team has delivered an exciting opportunity to the Company. These new families of not previously seen compounds are proving an extraordinarily rich source of potential new therapeutics. It is remarkable that the same underlying molecular structure can yield compounds of such diverse biological activity. This pleiotropy is what makes this family of compounds so valuable.”

“The lodgement of this patent also opens the way for our collaborators to present data for conference presentations and publications where disclosure of molecular structure is required,” Kelly added.

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’). The Novogen Group includes a New Haven CT – based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell’s cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our website: www.novogen.com

For more information please contact:

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.  The Company has tried to identify such forward-looking statements by use of such words as “expects,” “appear,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “should,” “would,”  “may,” “target,”  “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.  Such statements include, but are not limited to any statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, and any other statements that are not historical facts.  Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to events that could slow or prevent products coming to market, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to the Company’s two proprietary technology platforms, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.  Such statements are based on management’s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.  Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

(CDTI) Appoints International Automotive Industry Veteran Dr. Till Becker to Board

OXNARD, Calif., Feb. 11, 2015  — Clean Diesel Technologies, Inc. (Nasdaq:CDTI) (“CDTi” or “the Company”), a leader in advanced emission control technology, appointed Dr. Till Becker to the Company’s Board of Directors, effective February 9, 2015, increasing the number of directors to six. Dr. Becker will serve on the Technology Committee.

“Dr. Becker’s extensive international automotive leadership experience will be a valuable resource during CDTi’s transition from an emissions control manufacturer to an advanced materials technology company,” said Chairman Charles Engles, Ph.D. “CDTi plans to broadly commercialize its new advanced low- and zero-platinum group metal technologies, featuring its breakthrough Spinel™ technology.  Dr. Becker’s in-depth understanding of the global automotive supply chain and his contacts there will help guide the Company to the next stage of its growth and evolution. The Board joins me in welcoming him to CDTi.”

“CDTi’s Spinel™ technology platform represents an important breakthrough in clean air solutions,” Dr. Becker stated. “I look forward to working with the Company’s executive leadership team and Board of Directors to realize the potential of the Company’s advanced materials technology strategy and drive CDTi toward future success.”

Dr. Becker has more than 25 years of international experience in the automotive, consumer goods and energy industries and an extensive background in corporate restructuring and M&A transactions. He was at Daimler AG from 1987 to 2006, where he ran major international subsidiaries and served as Executive Vice President of the parent company. He served as Chairman and CEO of Daimler Northeast Asia, Mercedes-Benz Türk A.S., Istanbul, Mercedes-Benz India Pvt. Ltd. and Mercedes-Benz Portugal SA. In 2013, Dr. Becker served as CEO of Hess AG, a provider of world-class lighting systems, where he implemented a successful restructuring plan that led to the company’s sale. From 2010 to 2011, he served as interim CEO of MPS Micropaint Holding AS, an international distributor of premium spot repair systems for small paint damage to automobiles and as an advisor to RealEyes GmbH, a three-dimensional display imaging firm. From 2008 to 2010, Dr. Becker served as an advisor to Capital Dynamics Ltd., an independent, global asset management firm that invests in private equity and clean energy infrastructure.   Dr. Becker currently serves as a Senior Advisor at Global Board Room Advisors, an Asia-focused M&A consulting firm which he co-founded in 2011. He also serves as Senior Advisor to Holland Private Equity Growth Capital, an investment firm focused on growth-stage investments in small to mid-market technology companies in the Benelux and Germany, and Senior Consultant to Artris Management Ltd., a European consulting and M&A company. Dr. Becker holds a law degree from the University of Münster.

About CDTi

CDTi manufactures and distributes vehicle emissions control products that leverage its advanced materials technology. CDTi utilizes its proprietary patented Mixed Phase Catalyst (MPC®) technology and other related technologies to provide high-value sustainable solutions to reduce emissions, increase energy efficiency and lower the carbon intensity of on- and off-road combustion engine systems. Reflecting its continued focus on innovation, CDTi is developing and commercializing proprietary advanced low-platinum group metal (PGM) catalysts including synergized-PGM (SPGM™), as well as zero-PGM (ZPGM™) catalysts. CDTi is headquartered in Oxnard, California and has operations in the U.K., Canada, France, Japan and Sweden. For more information, please visit www.cdti.com.

Forward-Looking Statements

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact should be considered forward-looking statements. You can identify these forward-looking statements by the use of the words “believes”, “expects”, “anticipates”, “plans”, “may”, “will”, “would”, “intends”, “estimates”, and other similar expressions, whether in the negative or affirmative. Forward-looking statements are based on a series of expectations, assumptions, estimates and projections which involve substantial uncertainty and risk. In this document, the Company includes forward looking statements regarding (a) its growth, future success, strategies and focus on innovation; (b) the effect Dr. Becker may have on the Company; (c) its transition to an advanced materials technology company; (d) its plans to broadly commercialize its new technologies; (e) the benefits of its technology; (f) the achievement of intended results; and (g) its ability to develop and commercialize proprietary advanced low- or zero-PGM catalysts. In general, actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including, but not limited, to (i) any inability by CDTi to (1) reduce costs; (2) increase sales; (3) realize the benefits of investments; (4) obtain sufficient funding; (5) realign its strategic path; (6) execute its strategic priorities; (7) commercialize its technology due to agreements with third parties; (8) protect its intellectual property; (9) obtain verifications, approvals or market acceptance of its products or technology; (10) attract or retain qualified personnel; or (11) achieve anticipated results; (ii) changes in or lack of enforcement of or funding for emissions programs, regulations or standards; (iii) competitive conditions; (iv) prices of PGM and rare earth metals; (v) intellectual property infringement claims by third parties; (vi) supply or delivery interruptions, limitations or failures; (vii) the loss of one or more major customers; (viii) product malfunctions, design failures or the inability to meet emissions control standards; and (ix) other risks and uncertainties discussed or referenced in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. In addition, any forward-looking statements represent the Company’s estimates only as of the date of such statements and should not be relied upon as representing the Company’s estimates as of any subsequent date. The Company specifically disclaims any obligation to update forward-looking statements. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

CONTACT:  Becky Herrick or Cathy Mattison
          LHA (IR Agency)
          +1 415 433 3777
          bherrick@lhai.com
          cmattison@lhai.com

(DGLY) Expands Commercial Customer Base for Cloud-Based FleetVU Manager Software

Recurring Revenue Cloud Solution Rapidly Growing in Commercial Markets

(PRSS) Announces Definitive Agreement to Sell Art Business to Circle Graphics, Inc.

Divestiture Accelerates Strategic Goals of Streamlining the Business and Focusing on CafePress.com Company Announces Preliminary Fourth Quarter Results and Date of Earnings Call

CafePress Inc. (NASDAQ:PRSS), the on-demand printing leader, today announced that it has reached a definitive agreement to divest its Art business. The divesture is a component of the Company’s strategy to streamline operations, optimize its product offerings and focus on growing its core business, CafePress.com.

Under terms of the agreement, CafePress would sell its Art business to privately held Circle Graphics, Inc., for approximately $31.5 million in cash. Although no assurances as to timing can be made, the transaction is expected to close during the first quarter of 2015, and is subject to certain adjustments and closing conditions. The Art business represented approximately 20 percent of CafePress’s total revenues in 2014.

“We believe this transaction will advance the important goals of our strategic evaluation process, namely simplifying our business, significantly strengthening our balance sheet and aligning our expense run-rate with our revenues. This move is intended to accelerate our ability to concentrate on optimizing our business and increasing stockholder value,” said CEO Fred Durham.

Preliminary Fourth Quarter Results

CafePress also announced preliminary, unaudited fourth quarter revenue results. For the fourth quarter of 2014 CafePress expects to report revenues in the range of $82 – $84 million and expects its earnings per share to be substantially below analyst consensus estimates. CafePress ended the year with approximately $30 million in cash as of December 31, 2014.

Fourth Quarter and Fiscal Year 2014 Conference Call Information

CafePress Inc. announced it will report its fourth quarter and fiscal year 2014 financial results for the period ended December 31, 2014 following the close of market on Wednesday, February 25, 2015. On that day, management will hold a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) to review and discuss the Company’s results. To participate on the live call, analysts and investors should dial 1-888-438-5519 at least ten minutes prior to the call. CafePress will also offer a live and archived webcast of the conference call, accessible from the “Investors” section of the Company’s web site at http://investor.cafepress.com/.

Notice Regarding Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements as to the likelihood, timing, proceeds and impact of the divestiture transaction on the Company’s goals, focus, and financial performance, including statements regarding the Company’s belief that the divestiture transactions will advance the goals of its strategic evaluation process, including simplifying its business, significantly strengthening its balance sheet and aligning its expense run-rate with revenues, statements that the divestiture transaction is intended to accelerate the Company’s ability to concentrate on optimizing its business and increasing stockholder values, statements about the Company’s expectations for fourth quarter financial results, including GAAP and non-GAAP revenue, and statements about the Company’s strategic and investment plans, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, but not limited to, risks relating to the Company’s ability to successfully close and divest its art business, the impact of the divestiture on the Company’s operations and financial performance, the Company’s ability to compete effectively, economic downturns, the impact of seasonality on the Company’s business. The estimates of fourth quarter revenue are preliminary and so subject to change. There can be no assurance that when the company completes its review of these results, its final determination of fourth quarter 2014 revenues and earnings will be different than the preliminary estimates described above. More information regarding these and other risks, uncertainties and factors is contained in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC, and in other reports filed by the Company with the SEC from time to time. These forward-looking statements speak only as of the date hereof. CafePress disclaims any intention or obligation to update or revise any forward-looking statements.

About CafePress [PRSS]:

CafePress is passionate about helping individuals forge connections and celebrate their identities, interests and obsessions through unique products and content.

Our customers include people from all walks of life who are drawn to products that are emotional, inspirational and motivational. CafePress continues to enhance its assortment of designs, brands, images and base goods within its library of print-on-demand products. This expansion solidifies CafePress’ reputation as the ultimate resource for creating connections and bring-to-life creativity, opinions and passions. For more information, visit www.cafepress.com or connect with CafePress on Facebook, Twitter, Pinterest or YouTube.

(BLDP) Inks US$80M+ Deal With Volkswagen

– Transaction deepens strategic partnership

VANCOUVER, Canada and INGOLSTADT, Germany, Feb. 11, 2015  – Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) today announced that the Company has entered into a Technology Solutions transaction with Volkswagen Group (Volkswagen AG, www.volkswagenag.com and Audi AG, www.audi.com) for an aggregate amount of approximately US$80 million for the transfer of certain automotive-related fuel cell intellectual property (IP) and a two-year extension of an engineering services contract.

Prof. Dr. Ulrich Hackenberg, Member of the Board of Management for Technical Development at AUDI AG and Coordinator of the Technical Development of all brands in the Volkswagen Group said, “Audi, VW and the Volkswagen Group are very pleased with the acquisition of a world-class automotive fuel cell patent portfolio. We believe that this portfolio, together with the combined fuel cell skills and expertise of our group and Ballard, will underpin our ability to play a leading role in fuel cell automotive development and commercialization.”

Randy MacEwen, Ballard President and CEO said, “This transaction extends and deepens our relationship with the Volkswagen Group, a leading global automotive manufacturer. The IP transfer surfaces significant value for Ballard. And, extension of the engineering services contract reflects a growing positive sentiment toward fuel cells within the automotive sector, along with the outstanding progress made to date in our work with Volkswagen Group on its fuel cell car programs.”

Transfer of Automotive-Related IP

Ballard will transfer the automotive-related portion of fuel cell IP assets previously acquired from United Technologies Corporation, in return for payments from Volkswagen Group totaling US$50 million, a majority of which is expected to be received at the closing of the transaction during the current quarter. The remainder is expected to be received in early 2016.

Ballard will retain a royalty-free license to utilize the IP transferred to Volkswagen Group in bus and non-automotive applications as well as for certain limited pre-commercial purposes in automotive applications.

Extension of Engineering Services Contract

The transaction also includes a 2-year extension, through March 2019, of the existing long-term engineering services agreement signed by Ballard and Volkswagen in 2013. This extension has an incremental value estimated at C$30-50 million (approximately US$24-40 million). Over the full 6-years, the contract has an estimated value of C$100-140 million (approximately US$80-112 million), and also includes a further optional 2-year extension.

Ballard’s ongoing engineering services contract with Volkswagen Group involves the design and manufacture of next-generation fuel cell stacks for use in the demonstration car program. Ballard engineers are leading critical areas of fuel cell product design – including the membrane electrode assembly (MEA), plate and stack components – along with certain testing and integration work.
Volkswagen Group’s commitment to, and progress in, fuel cell car development was underscored last November at the LA Auto Show, where fuel cell concept cars representing Volkswagen and Audi brand models were introduced: Golf SportWagen HyMotion, Passat HyMotion and Audi A7 Sportback h-tron quattro.

Mr. MacEwen added, “Ballard’s Technology Solutions group is helping customers accelerate fuel cell development through the application of our world-class, customized engineering services capability, along with access to our deep IP portfolio and related know-how. This transaction with Volkswagen marks a milestone in the growth and delivery of Ballard Technology Solutions.”

Ballard will provide further information regarding this transaction during the Company’s upcoming “2014 Results & 2015 Outlook” conference call, scheduled for 1:00 p.m. EST (10:00 a.m. PST) on Thursday, February 26, 2015.

About Ballard Power Systems

Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) provides clean energy products that reduce customer costs and risks, and helps customers solve difficult technical and business challenges in their fuel cell programs. To learn more about Ballard, please visit www.ballard.com.

This release contains forward-looking statements concerning anticipated market growth drivers, product attributes and corresponding value propositions for our customers. These forward-looking statements reflect Ballard’s current expectations as contemplated under section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any such forward-looking statements are based on Ballard’s assumptions relating to its financial forecasts and expectations regarding its product development efforts, manufacturing capacity, and market demand.

These statements involve risks and uncertainties that may cause Ballard’s actual results to be materially different, including general economic and regulatory changes, detrimental reliance on third parties, successfully achieving our business plans and achieving and sustaining profitability. For a detailed discussion of these and other risk factors that could affect Ballard’s future performance, please refer to Ballard’s most recent Annual Information Form. Readers should not place undue reliance on Ballard’s forward-looking statements and Ballard assumes no obligation to update or release any revisions to these forward looking statements, other than as required under applicable legislation.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.  The Ballard Common Shares have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

(AST) Completes Public Offering and Private Placement of Common Stock

MENLO PARK, Calif., Feb. 10, 2015  — Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the “Company”), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it has completed the previously announced underwritten public offering and concurrent private placement of its common stock.

The Company raised $5.5 million in aggregate gross proceeds from the public offering and the private placement, which it intends to use for the continued development of product candidates through clinical trials and for working capital and general corporate purposes.

“This investment by new and existing investors, as well as by management, demonstrates the continued confidence in our strategic direction and the progress achieved with respect to our two key clinical development programs that have the potential to address significant unmet medical needs using our pluripotent stem cell technology platform,” stated Pedro Lichtinger, President and CEO of Asterias. “Of our two lead product candidates, AST-OPC1 for the treatment of complete cervical spinal cord injury has been cleared for a Phase 1/2a clinical trial and AST-VAC2 is expected to enter a Phase 1 clinical trial. Our strengthened cash position, combined with the non-dilutive funding that we secured last year from partnerships with leading scientific institutions, provides resources and flexibility required to execute our strategic plan in order to further advance these two products through meaningful clinical milestones.”

MLV & Co. LLC served as Sole Book-Running Manager for the public offering.  The common stock sold in the public offering was offered by the Company pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission.

About Asterias Biotherapeutics

Asterias’ core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Asterias plans to develop therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields having major unmet needs and without adequate therapies available. Asterias initial focus is on two clinical stage programs including oligodendrocyte progenitor cells (AST-OPC1) for spinal cord injuries and antigen-presenting allogeneic dendritic cells (AST-VAC2) for lung cancer.

Asterias is a majority-owned subsidiary of BioTime, Inc., (NYSE MKT: BTX), a biotechnology company engaged in research and product development in the field of regenerative medicine.

FORWARD-LOOKING STATEMENTS

Certain statements contained herein are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias’ filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements

(CLIR) Jeffrey L. Ott Joins ClearSign Board of Directors

SEATTLE, Feb. 10, 2015  — ClearSign Combustion Corporation (NASDAQ: CLIR), an emerging leader in combustion and emissions control technology for industrial, commercial and utility markets, today announced the appointment of Jeffrey L. Ott as an independent director of the Company, effective immediately.

Mr. Ott is the President and Chief Executive Officer of Quest Integrity Group, LLC, a platform company and a subsidiary of Team, Inc. (NYSE:TISI), with operations in advanced inspection and engineering assessment of critical energy infrastructure in the process, pipeline, production and power sectors.

“Jeff’s broad experience in the energy industry along with his depth of knowledge in investment banking will add a valuable perspective to our Board of Directors,” said Stephen E. Pirnat, ClearSign Chairman and CEO. “We appreciate his willingness to serve as a director and look forward to benefitting from his judgment and counsel.”

Mr. Ott has been involved with high-growth, industrial technology companies for over 25 years as an investor, director, advisor, and financier. His industry focus has included energy, automotive performance, software, process controls and NDT/E instrumentation. As a general partner at Gryphon Investors, he was responsible for managing the group’s middle market-focused technology investment interests. Mr. Ott previously managed the west coast private equity effort and technology investments as a general partner at Deutsche Bank Capital Partners and prior to that, led the global convertible and equity-linked capital markets effort for Bankers Trust. He began his career as an engineer in the Operations Analysis group at Rockwell International’s North American Aircraft. Mr. Ott holds a B.S. in Engineering Management and Operations Research from Southern Methodist University and an M.B.A. from the Amos Tuck School of Business at Dartmouth College.

About ClearSign Combustion Corporation

ClearSign Combustion Corporation designs and develops technologies that aim to improve key performance characteristics of combustion systems including energy efficiency, emissions control, fuel flexibility and overall cost effectiveness. Our patent-pending Duplex™ and Electrodynamic Combustion Control™ platform technologies improve control of flame shape and heat transfer and optimize the complex chemical reactions that occur during combustion in order to minimize harmful emissions. For more information about the Company, please visit www.clearsign.com

Cautionary note on forward-looking statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding the completion, timing and size of the proposed public offering.  Such forward looking statements involve risks and uncertainties, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering. Such statements involve known and unknown risks that relate to future events or future financial performance and the actual results could differ materially from those discussed in this communication. There can be no assurance that ClearSign will be able to complete the proposed public offering. Risks and uncertainties that may cause ClearSign’s actual results to differ materially from those discussed in this communication can be found in the “Risk Factors” section of ClearSign’s Form 10-K, Forms 10-Q and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and ClearSign assumes no responsibility to update or revise any forward-looking statements contained in this communication to reflect events, trends or circumstances after the date of this communication.

(XONE) North American Production Service Centers Now Certified for ISO 9001:2008

• ExOne’s Troy, Mich. and North Huntingdon, Pa. facilities join Auburn, Wash.; Houston, Texas; and Las Vegas, Nev. in full ISO 9001:2008 Certification
• All PSCs noted for quality management systems that meet ISO requirements

NORTH HUNTINGDON, Pa., Feb. 10, 2015 — The ExOne Company (Nasdaq:XONE), a global provider of three-dimensional printing machines and printed products to industrial customers, today announced that its production service centers (PSCs) in North Huntingdon, Pa. and Troy, Mich. have been certified to ISO 9001:2008 as Industrial Additive Manufacturers by DAS Certification. With the latest two facility certifications, all five of ExOne’s PSCs in North America now have ISO certification, joining ExOne’s other PSCs in Auburn, Wash., Houston, Texas, and Las Vegas, Nev. ISO 9001:2008 certification designates that the ExOne North Huntingdon and Troy facilities’ quality management systems conform to the specific requirements of the ISO (International Organization for Standardization).

The ISO 9001:2008 standard is based on eight quality management principles, including a strong customer focus, commitment of top management, a process approach and continuous improvement. Receiving ISO 9001:2008 certification helps ensure that ExOne’s customers receive consistently high quality products and services. To achieve the certification, ExOne had to demonstrate its consistent ability to provide products that meet customer and applicable statutory/regulatory requirements, while enhancing customer satisfaction through the effective application of the system. This includes processes for continuous improvement and the assurance of conformity to customer and statutory/regulatory requirements.

“Receiving ISO certification demonstrates that ExOne’s binder jetting 3D printing technology consistently meets our customers’ expectations and product quality standards for industrial usage,” said Tim Pierce, ExOne’s U.S. Chief Operating Officer. “By earning this certification at all of our North American facilities, ExOne customers recognize that they can achieve a high-level of service and quality regardless of their business region or printing application.”

ISO is the world’s largest developer of voluntary international standards. ISO 9001:2008 establishes the criteria for a quality management system and is implemented by more than one million companies and organizations in more than 170 countries.

For more information on ExOne and its binder jetting 3D printing technology, visit: www.exone.com.

About ExOne

ExOne is a global provider of 3D printing machines and printed products, materials and other services to industrial customers. ExOne’s business primarily consists of manufacturing and selling 3D printing machines and printing products to specification for its customers using its in-house 3D printing machines. ExOne offers pre-production collaboration and print products for customers through its eight PSCs, which are located in the United States, Germany, Italy and Japan. ExOne builds 3D printing machines at its facilities in the United States and Germany. ExOne also supplies the associated materials, including consumables and replacement parts, and other services, including training and technical support, necessary for purchasers of its machines to print products.

Safe Harbor Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects,” “estimates,” “projects,” “typically,” “anticipates,” “believes,” “appears,” “could,” “plan,” and other similar words. Such statements include, but are not limited to, statements concerning future revenue and earnings, involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, which include our ability to qualify more materials in which we can print; the availability of skilled personnel; the impact of increased operating expenses and expenses relating to proposed acquisitions, investments and alliances; our strategy, including the expansion and growth of our operations; the impact of loss of key management; our plans regarding increased international operations in additional international locations; sufficiency of funds for required capital expenditures, working capital, and debt service; the adequacy of sources of liquidity; expectations regarding demand for our industrial products, operating revenues, operating and maintenance expenses, insurance expenses and deductibles, interest expenses, debt levels, and other matters with regard to outlook; demand for aerospace, automotive, heavy equipment, energy/oil/gas and other industrial products; the scope, nature or impact of acquisitions, alliances and strategic investments and our ability to integrate acquisitions and strategic investments; liabilities under laws and regulations protecting the environment; the impact of governmental laws and regulations; operating hazards, war, terrorism and cancellation or unavailability of insurance coverage; the effect of litigation and contingencies; the impact of disruption of our manufacturing facilities or PSCs; the adequacy of our protection of our intellectual property; material weaknesses in our internal control over financial reporting and other factors disclosed in the Company’s Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Because they are forward-looking, these statements should be evaluated in light of important risk factors and uncertainties.

Should one or more of these risks or uncertainties materialize, or should any of ExOne’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. The Company disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this news release.

CONTACT: For more information, contact:

         Media:
         Justin Falce
         Burson-Marsteller
         (412) 394-6698
         justin.falce@bm.com

         Investors:
         Brian W. Smith
         ExOne, Chief Financial Officer
         (724) 765-1350
         brian.smith@exone.com

         Deborah K. Pawlowski/Karen L. Howard
         Kei Advisors LLC
         (716) 843-3908 / (716) 843-3942
         dpawlowski@keiadvisors.com /
         khoward@keiadvisors.com

(FSLR) & (AAPL) Strike Industry’s Largest Commercial Power Deal

First Solar, Inc. (Nasdaq: FSLR) today announced that Apple has committed $848 million for clean energy from First Solar’s California Flats Solar Project in Monterey County, Calif. Apple will receive electricity from 130 megawatts (MW)_AC of the solar project under a 25-year power purchase agreement (PPA), the largest agreement in the industry to provide clean energy to a commercial end user.

“Apple is leading the way in addressing climate change by showing how large companies can serve their operations with 100 percent clean, renewable energy,” said Joe Kishkill, Chief Commercial Officer for First Solar. “Apple’s commitment was instrumental in making this project possible and will significantly increase the supply of solar power in California. Over time, the renewable energy from California Flats will provide cost savings over alternative sources of energy as well as substantially lower environmental impact.”

The 2,900-acre California Flats Solar Project occupies 3 percent of a property owned by Hearst Corporation in Cholame, Calif. Construction is expected to begin in mid-2015, and to be completed by the end of 2016. The output of the remaining 150MW of the project will be sold to Pacific Gas & Electric under a separate long-term PPA, and the project is fully subscribed between the Apple and PG&E PPAs.

In January, the Monterey County Planning Commission unanimously approved the California Flats Solar Project, sending the project to the Monterey County Board of Supervisors, which will consider final approval of the project today.

Building on its proven record of developing, building and operating utility-scale solar power plants, First Solar has placed a strategic focus on directly providing large commercial and industrial customers with wholesale electricity through long-term agreements. This deal marks the first wholesale commercial and industrial PPA executed by First Solar.

About First Solar, Inc.

First Solar is a leading global provider of comprehensive photovoltaic (PV) solar systems which use its advanced module and system technology. The company’s integrated power plant solutions deliver an economically attractive alternative to fossil-fuel electricity generation today. From raw material sourcing through end-of-life module recycling, First Solar’s renewable energy systems protect and enhance the environment. For more information about First Solar, please visit www.firstsolar.com.

For First Solar Investors

This release contains forward-looking statements which are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements, among other things, concerning: our business strategy, including anticipated trends and developments in and management plans for our business and the markets in which we operate; future financial results, operating results, revenues, gross margin, operating expenses, products, projected costs, warranties, solar module efficiency and balance of systems (“BoS”) cost reduction roadmaps, restructuring, product reliability and capital expenditures; our ability to continue to reduce the cost per watt of our solar modules; our ability to reduce the costs to construct photovoltaic (“PV”) solar power systems; research and development programs and our ability to improve the conversion efficiency of our solar modules; sales and marketing initiatives; and competition. These forward-looking statements are often characterized by the use of words such as “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “foresee,” “likely,” “may,” “should,” “goal,” “target,” “might,” “will,” “could,” “predict,” “continue” and the negative or plural of these words and other comparable terminology. Forward-looking statements are only predictions based on our current expectations and our projections about future events. You should not place undue reliance on these forward-looking statements. We undertake no obligation to update any of these forward-looking statements for any reason. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these statements. These factors include, but are not limited to, the matters discussed in Item 1A: “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2013, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports filed with the SEC.

(PFNX) & (HSP) Collaboration To Develop And Commercialize Proposed LUCENTIS® Biosimilar

SAN DIEGO and LAKE FOREST, Ill., Feb. 10, 2015  — Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex’s biosimilar candidate to Genentech’s LUCENTIS^® (ranibizumab injection). LUCENTIS had estimated global sales of approximately $4 billion in 2014 and is part of the broader $6.7 billion intraocular anti-VEGF (vascular endothelial growth factor) therapeutic segment.

Under the terms of the collaboration, Pfenex will receive an upfront payment of $51 million once the collaboration receives antitrust approval, and, over the next five years and beyond, will be eligible to receive a combination of development and sales-based milestone payments up to an additional $291 million, and tiered double-digit royalty on net sales of the product.

Pfenex and Hospira will share the Phase 3 equivalence clinical trial costs, and Hospira will be responsible for manufacturing and commercializing the product worldwide. The collaboration will be governed by an Executive Steering Committee consisting of equal representation from Pfenex and Hospira. The agreement also allows for additional future product collaborations.

“We are extremely pleased to announce our collaboration with Hospira, a recognized world leader in biosimilars. This collaboration further validates the product development strength and capability of Pfenex as we continue to advance our pipeline of biosimilar candidates,” said Bertrand Liang, chief executive officer, Pfenex Inc.

Pfenex is currently conducting a Phase 1b/2a clinical trial where 24 patients have been randomized to receive monthly intraocular injections of PF582 or LUCENTIS for 3 doses and ongoing patient follow-up for 12 months. The clinical trial’s primary objective is to evaluate safety and tolerability of PF582, with secondary objectives including comparative pharmacokinetic (PK) and pharmacodynamic (PD) evaluations to help demonstrate biosimilarity to LUCENTIS.

“We are excited to be entering this collaboration with Pfenex for its biosimilar candidate to LUCENTIS, which we expect will expand Hospira’s biosimilars pipeline to include a new therapeutic area. Pfenex has established expertise in the development of biosimilars, leveraging its proprietary expression technology together with differentiated bioanalytical characterization capabilities,” said Sumant Ramachandra, M.D., Ph.D., senior vice president, chief scientific officer, Hospira. “We look forward to working closely with the Pfenex team to offer patients, physicians and healthcare systems a more affordable treatment option for retinal diseases.”

The agreement is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act.

About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company’s lead product candidate is PF582, a biosimilar candidate to LUCENTIS (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfenex Expression Technology^® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.

Pfenex has used, and intends to continue to use, its Investor Relations website (http://pfenex.investorroom.com), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit (http://pfenex.investorroom.com).

About Hospira
Hospira, Inc. is the world’s leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill. Learn more at www.hospira.com .

Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or Pfenex’s or Hospira’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern either of Pfenex’s or Hospira’s expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to: in the case of Pfenex, statements regarding the future potential of PF582, including future plans to develop, manufacture and commercialize PF582 and the potential to receive future milestone and royalty payments; and in the case of Hospira, its expectations regarding regulatory approvals, clinical trials and the actions of competitors. The companies’ expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, challenges inherent in creating and developing compounds and product candidates and economic, competitive, governmental, regulatory, legal, supply and other factors.  Information on these and additional risks affecting Hospira’s business and operating results are more fully discussed in the section entitled “Risk Factors” in its most recently filed annual report on Form 10-K, as updated by any subsequently filed quarterly report on Form 10-Q. Information on these and additional risks affecting Pfenex’s business and operating results are more fully discussed in the section entitled “Risk Factors” in its most recently filed quarterly report on Form 10-Q for the quarter ended September 30, 2014 and Pfenex’s subsequent periodic reports, including Pfenex’s Form 10-K for the year ended December 31, 2014, which is expected to be filed with the SEC in March of 2015. The forward-looking statements in this press release are based on information available as of the date hereof, and each of Pfenex and Hospira disclaims any obligation to update any forward-looking statements, except as required by law.

(ANTH) Completion of Interim Analysis, Phase 3 Blisibimod Trial for Systemic Lupus Erythematosus

— CHABLIS-SC1 study passes futility analysis and will continue to completion with an enhanced endpoint — Enrollment to be completed in 2015 with final data in Q3 2016 — Recent encouraging EMA feedback on BRIGHT-SC design to be incorporated prior to interim

HAYWARD, Calif., Feb. 10, 2015  — Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. An independent statistician conducted the interim futility analysis for the CHABLIS-SC1 study, evaluating the SRI-6 response at the 24 week time point. Enrollment in the trial is projected to conclude in mid-2015.

“While the results of the CHABLIS-SC1 interim futility analysis remain blinded to Anthera, we are very pleased that the study has passed this critical milestone and now look forward to finishing enrollment later this year,” said Dr. Colin S. Hislop, Anthera’s Chief Medical Officer.

Prior to the interim analysis and in response to recent input from the Company’s Scientific Advisory Board following the publication of clinical data from other Lupus studies with BAFF inhibitors, the Company modified the primary endpoint of CHABLIS-SC1 from SRI-8 response to SRI-6 response, which was previously a secondary endpoint of the study.  SRI-8 will remain a key secondary endpoint of the study. The Systemic Lupus Erythematosus Response Index (SRI) is an approved endpoint recognized by the FDA for previously approved therapeutics.

“Based on the wealth of new information regarding the treatment of SLE and BAFF inhibition, we are fortunate to have had the opportunity to adjust our trial design,” said Dr. Colin S. Hislop. “The SRI-6 endpoint has a history of consistency across multiple trials and represents the best possibility for success. Maintaining the SRI-8 endpoint as a key secondary endpoint can maximize our commercial opportunity for the severe patients we are enrolling in the CHABLIS-SC1 study.”

Anthera has also completed a Scientific Advice Process meeting with the European Medicines Agency (EMA) regarding the blisibimod development program for the treatment of IgA Nephropathy (IgAN).  Earlier this quarter the Company obtained written feedback regarding the acceptability of a single pivotal study as the initial basis for a conditional market authorization application (MAA) in the European Union utilizing proteinuria as the primary endpoint.  In addition, the EMA also provided recommendations to address treatment duration, durability of response and need for re-treatment in the BRIGHT-SC study.  Anthera and its Japanese development partner Zenyaku Koygo Co., Ltd. plan to incorporate them in a protocol amendment prior to the planned interim analysis for the BRIGHT-SC study which will be completed later this quarter.

“We are pleased by the feedback from the EMA on the IgAN development program, which supports our global approach in IgAN.  This comes at a time when we are actively expanding our recruitment efforts throughout the world,” said Dr. Colin S. Hislop.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including systemic lupus erythematosus, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis.

About Blisibimod

Anthera is developing blisibimod, a selective inhibitor of B-cell activating factor (BAFF), to explore its clinical utility in various autoimmune diseases including systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod is a novel FC-fusion protein, or peptibody, and is distinct from an antibody. BAFF is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells. Abnormal elevations of B-cells and BAFF may lead to an overactive immune response, which can damage normal healthy tissues and organ systems. Multiple clinical studies with BAFF antagonists have reported the potential benefit of BAFF inhibitors in treating patients with lupus and IgAN.

About Sollpura (liprotamase)

Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis, and potentially other diseases. EPI is characterized by low absorption of fat and other nutrients due to a reduction in digestive enzymes produced by the pancreas.  Unlike other enzyme products for EPI, Sollpura’s chemical characteristics make it ideal for formulation as either a capsule or sachet product for co-administration with a variety of food products.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as “estimate,” “intend,” “anticipate,” “believe,” “plan,” “goal,” “expect,” “project,” or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera’s expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera’s public filings with the SEC, including Anthera’s Annual Report on Form 10-K for the year ended December 31, 2013 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2014.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510.856.5598.

(IPWR) Names Ideal Power as Aegis Partner and Orders More Than 1 MW of Converters